We hope you'll join us for our 4/23 webinar on using data tables to apply reference ranges and AE codes in OC4. For more information and to register, visit https://register.gotowebinar.com/register/2882170018956684555

unsuscribe

unsuscribe

------------------------------------------------------------------------------------------------------------------------
ppa. Dr. Sven Romer (Project Manager/ CRA)
CROLLL GmbH
Wörnitzstr. 115 a / Tel.: 0049 911/25 26 88-22 Sitz der Gesellschaft: Oberasbach
D-90449 Nürnberg / Fax: 0049 911/25 26 88-40 Geschäftsführer: Christiane Leikam
E-mail: [email protected] Amtsgericht Fürth: HRB 8840


Von: [email protected] [mailto:[email protected]] Im Auftrag von Paul Galvin
Gesendet: Dienstag, 12. August 2008 21:54
An: [email protected]
Betreff: RE: [Users] create new study - study phase

Hi Shmulik,

Thank you for your feedback on the phases of a study for medical devices. If you could provide a list of the particular phases for a medical device study, we can look to see if we can integrate those options in the creation of a new study in OpenClinica for 2.5.

If we can not integrate the options into 2.5, we can look to provide them as an update in the first maintenance release after 2.5

Thanks,
Paul
Sent: Tuesday, August 12, 2008 10:50 AM
To: [email protected]
Subject: [Users] create new study - study phase

Hi, Paul and Tom ,
As our firm mostly work with medical devices and not with drugs the study phases in the new study form are not relevant. It will be useful if you can add different phases for medical devices (e.g. feasibility study, pivotal study etc..)
Best regards,
Shmulik Adler
Clinical Trials manager.
****************************************
A. Stein - Regulatory Affairs Consulting
Beit Hapaamon (Suite 102)
20 HaTaas Str. (P.O.B. 124)
Kfar Saba 44425 ISRAEL
Tel: +972-9-7670002
Fax: +972-9-7668534
E-mail: [email protected]
*****************************************
This message and any included attachments are from A. Stein - Regulatory Affairs Consulting and are intended only for the addressee(s). The information contained herein may include trade secrets or privileged or otherwise confidential information. Unauthorized review, forwarding, printing,copying, distributing, or using such information is strictly prohibited and may be unlawful. If you received this message in error, or have reason to believe you are not authorized to receive it, please promptly delete this message and notify the sender by e-mail.
This discussion has been closed.